“Mild dysglycemia” in type 2 diabetes. To be neglected or not?

The now available incretin-based therapies, and more specifically the DPP-4 inhibitors provide the clinician with the possibility to reduce or eradicate both the dawn phenomenon and post-meal glucose excursions with minimal side effects (Journal of Diabetes and Its Complications)